Intensity Therapeutics Receives 180-Day Nasdaq Compliance Extension
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Newsfilter
- Compliance Extension: Intensity Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share, allowing the company until June 1, 2026, to regain compliance and avoid delisting risks.
- Market Reaction: While the extension notification does not immediately affect the company's stock listing or trading, it must maintain a compliant price for at least ten consecutive business days during the extension period to ensure continued listing on Nasdaq.
- Clinical Progress: Intensity is conducting multiple clinical trials, including a Phase 1/2 study for metastatic cancers and a Phase 2 randomized controlled trial for locally advanced breast cancer, demonstrating the potential of its novel tumor treatment approach to shift cancer treatment paradigms.
- Future Outlook: The company plans to actively monitor its stock's closing price during the extension period and take necessary actions to regain compliance, indicating its commitment to future growth and investor confidence.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on INTS
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.382
Low
1.50
Averages
3.33
High
5.00
Current: 0.382
Low
1.50
Averages
3.33
High
5.00
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensity Therapeutics Highlights 2025 Milestones and 2026 Strategic Priorities
- Clinical Validation: Intensity Therapeutics' peer-reviewed publication in BioMedicine confirms the clinical potential of INT230-6, reinforcing the company's scientific foundation in cancer treatment and providing robust support for future capital operations and clinical trials.
- Successful Capital Raising: The company has successfully raised funds, ensuring sufficient capital to support its R&D projects, expected to continue into 2027, which not only enhances financial stability but also lays the groundwork for long-term shareholder value creation.
- Clinical Trial Progress: INT230-6 has completed two clinical studies involving over 200 patients and has initiated a Phase 3 trial for soft tissue sarcoma, demonstrating its potential in treating refractory cancers and possibly transforming the cancer treatment landscape.
- Strategic Priorities: The company plans to focus on generating high-quality clinical data and additional peer-reviewed publications in 2026 while enhancing regulatory engagement to ensure market access and long-term success for its products.
Continue Reading
Everything You Should Know About the Rating Upgrade to Buy for Intensity Therapeutics Inc. (INTS)
Zacks Rank Upgrade: Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential stock price increases.
Earnings Estimate Revisions: The Zacks rating system, which focuses on earnings estimate revisions, shows a strong correlation with stock price movements, making it a valuable tool for investors.
Analyst Sentiment: Over the past three months, analysts have raised their earnings estimates for Intensity Therapeutics by 7.9%, reflecting an improving outlook for the company's business.
Investment Opportunities: The Zacks Rank system categorizes stocks based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, suggesting that INTS could outperform the market in the near term.
Continue Reading